Navigation Links
Frost & Sullivan Applauds SHL Telemedicine for Excellence in Product Innovation
Date:4/1/2009

LONDON, April 1 /PRNewswire/ -- The '2008 European Telemedicine Systems for Cardiac Monitoring Product Innovation of the Year Award' is presented to SHL Telemedicine Ltd. in recognition of its next generation personal ECG device - the CardioSen'C(TM). This full 12 lead ECG personal digital cellular transmitter is a monitoring system that uses either cellular network (GPRS) or public switched telephone network (PSTN) to transmit real-time medical cardiological data remotely. It effectively fulfils the need for an end-user friendly system.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"The CardioSen'C(TM) is a revolutionary product that transmits digital encoded ECG data through the cellular network (GPRS) and allows for comparable ECG accuracy due to the elimination of background noise present when using acoustic transmission against many of the present generation wireless communication modalities such as WiFi or Bluetooth," notes Frost & Sullivan Research Analyst Abhishek Dutta. "In addition, the device enables medical professionals at the telemedicine centre to remotely operate and control the device, which promises calm, clear and effortless transmission on the part of the end user."

The CardioSen'C(TM) transmits in real time to SHL's telemedicine centre, providing a patient's full 12 lead ECG for the purpose of remote, real-time diagnosis of arrhythmia, ischemia, and myocardial infarction (MI). The ECG is then analysed by medical professionals at SHL's telemedicine centre.

"This, together with a clinical description given by the patient, provides medical professionals with the critical data needed to assess the situation and provide medical assistance, if necessary," says Dutta. "This telemedicine service helps to drastically reduce morbidity and mortality rates following an acute MI or other severe cardiac incidents."

SHL Telemedicine performed an extended six-month Acute Coronary Syndrome Israel Survey (ACSIS) in 2004 with the objective of comparing the one-year survival rates of SHL telemedicine subscribers against ACSIS participants who survived hospitalisation after sustaining an acute MI. Results showed that in spite of having more risk factors than ACSIS subjects, SHL telemedicine subscribers had significantly higher survival rates at one-year compared to ACSIS patients.

"We are very pleased to receive this award, which is further evidence of our leadership and technological excellence in the field of telemedicine," comments Erez Alroy, Co-CEO of SHL Telemedicine.

The Frost & Sullivan Award for Product Innovation is presented each year to the company that has demonstrated excellence in new products and technologies within its industry. The recipient company has shown innovation by launching a broad line of emerging products and technologies.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About SHL Telemedicine Ltd.

SHL Telemedicine Ltd. specialises in developing and marketing advanced personal telemedicine systems as well as providing comprehensive telemedicine solutions including medical call centres to individuals and to the healthcare community. As a leading provider of remote health services in cardiology and in other medical areas, SHL maintains business operations in Europe, mainly through PHTS in Germany, its fully owned subsidiary, and at its home market in Israel. In the US, certain SHL telemedicine products are distributed by Philips Healthcare. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). More information available at: www.shl-telemedicine.com

    SHL Telemedicine Contact Information
    Erez Alroy, Co-CEO, Phone: +972 3561 22 12, ereza@shl-telemedicine.com
    Assistant: Pauline Shavit, Phone: +972 3561 22 12,

    Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40,
    shl@irf

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.

    Frost & Sullivan Contact Information

    Jasmine Malone - Promotions Coordinator
    Phone: 0044 207 915 7869
    E-Mail:jasmine.malone@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture
2. Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications
3. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
4. Frost & Sullivan Award Highlights Opportunity for Main Street Biotech
5. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
6. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
7. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
8. Frost & Sullivan: In Vitro Diagnostics Market
9. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
10. Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG
11. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market ... 2013. The market is expected to grow at a five-year compound ... from $50.6 billion in 2015 to $96.6 billion in 2020. ... (2015 to 2020) are discussed. As well, new products approved in ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016   ... the first pluripotent stem cell-derived islet replacement therapy for ... two presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, ... 22nd to 25th at Moscone West in San Francisco.  ... Details of the presentations are as follows:Event: , Focus ...
Breaking Biology Technology:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):